<?xml version='1.0' encoding='utf-8'?>
<document id="27000758"><sentence text="Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies."><entity charOffset="68-80" id="DDI-PubMed.27000758.s1.e0" text="Paritaprevir" /></sentence><sentence text="Paritaprevir is a direct-acting antiviral agent that is a component of approved multidrug regimens used in the treatment of hepatitis C virus (HCV) infection"><entity charOffset="0-12" id="DDI-PubMed.27000758.s2.e0" text="Paritaprevir" /></sentence><sentence text=" A population pharmacokinetic model for paritaprevir was developed using data from formulation, bioavailability, and drug-drug interaction studies that evaluated the pharmacokinetics of paritaprevir (coadministered with ritonavir to enhance exposure) with or without ombitasvir and/or dasabuvir at different paritaprevir dose levels"><entity charOffset="40-52" id="DDI-PubMed.27000758.s3.e0" text="paritaprevir" /><entity charOffset="186-198" id="DDI-PubMed.27000758.s3.e1" text="paritaprevir" /><entity charOffset="220-229" id="DDI-PubMed.27000758.s3.e2" text="ritonavir" /><entity charOffset="267-277" id="DDI-PubMed.27000758.s3.e3" text="ombitasvir" /><entity charOffset="285-294" id="DDI-PubMed.27000758.s3.e4" text="dasabuvir" /><entity charOffset="308-320" id="DDI-PubMed.27000758.s3.e5" text="paritaprevir" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e0" e2="DDI-PubMed.27000758.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e0" e2="DDI-PubMed.27000758.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e0" e2="DDI-PubMed.27000758.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e0" e2="DDI-PubMed.27000758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e0" e2="DDI-PubMed.27000758.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e0" e2="DDI-PubMed.27000758.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e1" e2="DDI-PubMed.27000758.s3.e1" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e1" e2="DDI-PubMed.27000758.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e1" e2="DDI-PubMed.27000758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e1" e2="DDI-PubMed.27000758.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e1" e2="DDI-PubMed.27000758.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e2" e2="DDI-PubMed.27000758.s3.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e2" e2="DDI-PubMed.27000758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e2" e2="DDI-PubMed.27000758.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e2" e2="DDI-PubMed.27000758.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e3" e2="DDI-PubMed.27000758.s3.e3" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e3" e2="DDI-PubMed.27000758.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e3" e2="DDI-PubMed.27000758.s3.e5" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e4" e2="DDI-PubMed.27000758.s3.e4" /><pair ddi="false" e1="DDI-PubMed.27000758.s3.e4" e2="DDI-PubMed.27000758.s3.e5" /></sentence><sentence text="" /><sentence text="A non-linear mixed-effects modeling approach was applied to data from 12 phase I, single- and multiple-dose studies that enrolled a total of 369 healthy volunteers" /><sentence text=" Age, sex, race, ethnicity, body weight, body surface area, body mass index, and baseline creatinine clearance were evaluated as covariates during model development"><entity charOffset="90-100" id="DDI-PubMed.27000758.s6.e0" text="creatinine" /></sentence><sentence text=" In addition, the influences of dose, formulation, and concomitant medications (e" /><sentence text="g" /><sentence text=" ombitasvir and dasabuvir) on paritaprevir bioavailability were included in the model"><entity charOffset="1-11" id="DDI-PubMed.27000758.s9.e0" text="ombitasvir" /><entity charOffset="16-25" id="DDI-PubMed.27000758.s9.e1" text="dasabuvir" /><entity charOffset="30-42" id="DDI-PubMed.27000758.s9.e2" text="paritaprevir" /><pair ddi="false" e1="DDI-PubMed.27000758.s9.e0" e2="DDI-PubMed.27000758.s9.e0" /><pair ddi="false" e1="DDI-PubMed.27000758.s9.e0" e2="DDI-PubMed.27000758.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27000758.s9.e0" e2="DDI-PubMed.27000758.s9.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s9.e1" e2="DDI-PubMed.27000758.s9.e1" /><pair ddi="false" e1="DDI-PubMed.27000758.s9.e1" e2="DDI-PubMed.27000758.s9.e2" /></sentence><sentence text="" /><sentence text="A two-compartment model with first-order absorption and elimination optimally described paritaprevir plasma concentration-time data"><entity charOffset="88-100" id="DDI-PubMed.27000758.s11.e0" text="paritaprevir" /></sentence><sentence text=" Paritaprevir bioavailability was formulation- and dose-dependent, and increased supraproportionally"><entity charOffset="1-13" id="DDI-PubMed.27000758.s12.e0" text="Paritaprevir" /></sentence><sentence text=" The accumulation of paritaprevir was 1"><entity charOffset="21-33" id="DDI-PubMed.27000758.s13.e0" text="paritaprevir" /></sentence><sentence text="57-fold on repeated dosing compared with the first dose" /><sentence text=" Coadministration of dasabuvir increased paritaprevir bioavailability by 59Â %; however, ombitasvir coadministration did not affect the pharmacokinetic profile of paritaprevir"><entity charOffset="21-30" id="DDI-PubMed.27000758.s15.e0" text="dasabuvir" /><entity charOffset="41-53" id="DDI-PubMed.27000758.s15.e1" text="paritaprevir" /><entity charOffset="88-98" id="DDI-PubMed.27000758.s15.e2" text="ombitasvir" /><entity charOffset="162-174" id="DDI-PubMed.27000758.s15.e3" text="paritaprevir" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e0" e2="DDI-PubMed.27000758.s15.e0" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e0" e2="DDI-PubMed.27000758.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e0" e2="DDI-PubMed.27000758.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e0" e2="DDI-PubMed.27000758.s15.e3" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e1" e2="DDI-PubMed.27000758.s15.e1" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e1" e2="DDI-PubMed.27000758.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e1" e2="DDI-PubMed.27000758.s15.e3" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e2" e2="DDI-PubMed.27000758.s15.e2" /><pair ddi="false" e1="DDI-PubMed.27000758.s15.e2" e2="DDI-PubMed.27000758.s15.e3" /></sentence><sentence text=" No subject-specific covariate influenced the paritaprevir pharmacokinetics"><entity charOffset="46-58" id="DDI-PubMed.27000758.s16.e0" text="paritaprevir" /></sentence><sentence text=" The pharmacokinetic model was robust in bootstrap evaluations and was consistent with observed data based on diagnostic goodness-of-fit plots and visual predictive checks" /><sentence text="" /><sentence text="The complex pharmacokinetics of paritaprevir were well described by the model, which can be used as a basis for clinical trial dosing and further evaluations in patients with HCV"><entity charOffset="32-44" id="DDI-PubMed.27000758.s19.e0" text="paritaprevir" /></sentence><sentence text="" /></document>